✦ LIBER ✦

Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics

✍ Scribed by Marina Papoutsaki; Maria-Sole Chimenti; Antonio Costanzo; Marina Talamonti; Arianna Zangrilli; Alessandro Giunta; Luca Bianchi; Sergio Chimenti

Book ID: 116583043
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 440 KB
Volume: 57
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2006.12.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sustained clinical efficacy and safety o

Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis (PsA): 2-year results from an open-label extension study

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Long-term efficacy and safety of adalimu

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

✍ Kenneth Gordon; Kim Papp; Yves Poulin; Yihua Gu; Stephen Rozzo; Eric H. Sasso 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Efficacy, safety and medication cost imp

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

✍ C. Leonardi; J.M. Sobell; J.J. Crowley; U. Mrowietz; Y. Bao; P.M. Mulani; Y. Gu; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 877 KB

Oral eltrombopag for up to three years i

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study

✍ Shinya Katsutani, Yoshiaki Tomiyama, Akiro Kimura… 📂 Article 📅 2013 🏛 Carden Jennings Publishing 🌐 English ⚖ 241 KB

An open-label pilot study of the effecti

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

✍ Arie E. van der Bijl; Ferdinand C. Breedveld; Christian E. Antoni; Joachim R. Ka 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 182 KB

Gefitinib versus pemetrexed as second-li

Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01) : An open-label, phase 3 trial

✍ Jong-Mu Sun; Ki Hyeong Lee; Sang-we Kim; Dae Ho Lee; Young Joo Min; Hwan Jung Yu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB